H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE...
News
Institute of Biomedical Research Corp Announces Purchase of Biomedical and Nutraceutical Assets
SEATTLE, WA, July 22, 2022 (GLOBE NEWSWIRE) -- Institute of Biomedical Research Corp. (OTC Pink: MRES), a diversified biomedical company,...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
CBO Sebastian Marx Image of ITM SE CBO Sebastian MarxGarching / Munich, July 22, 2022 – ITM Isotope Technologies Munich...
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox
COPENHAGEN, Denmark, July 22, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for...
Pixium Vision announces its financial results for H1 2022 and provides a business update
Pixium Vision announces its financial results for H1 2022 and provides a business update Cash position at 30 June 2022:...
Addex Raises $4.2 million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
Simply Better Brands Corp. Announces a Non-Brokered Private Placement of up to $9.1 Million Secured Convertible Debentures and up to $3.25 Million Common Shares to Reduce Debt and Fuel Growth
VANCOUVER, British Columbia, July 21, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands”) (TSX...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ – First Disease-Modifying Treatment for AADC Deficiency
First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint’s SmartFlow® Neuro CannulaSOLANA BEACH, Calif.,...
Zest Dental Solutions Protects LOCATOR® With Court Ruling
Decision helps assure Zest customers receive genuine LOCATOR® products LOCATOR Attachment System Genuine LOCATOR from Zest DentalCARLSBAD, Calif., July 21,...
Progyny, Inc. Announces Details for Its Second Quarter 2022 Results Report
NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility...
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022
Conference call to occur at 4:30pm ET on August 4EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc....
Motus GI to Release Second Quarter Results and Provide a Business Update on August 11
FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"),...
Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical...
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body...
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE...
Health Catalyst to Announce Second Quarter 2022 Operating Results and Host Conference Call on Thursday, August 4, 2022
SALT LAKE CITY, July 21, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of...
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to...